XSpray Pharma AB (6XP.F)
| Previous Close | 3.3850 |
| Open | 3.4000 |
| Bid | 3.3000 x N/A |
| Ask | 3.6950 x N/A |
| Day's Range | 3.2750 - 3.4000 |
| 52 Week Range | 2.5000 - 4.3200 |
| Volume | |
| Avg. Volume | 2 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Business WireFDA Accepts Xspray Pharma’s NDA-resubmission for Dasynoc® – PDUFA Date set to 31 July 2024
STOCKHOLM, February 12, 2024--Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY): The U.S. Food and Drug Administration (FDA) has accepted the resubmission of Xspray Pharma’s New Drug Application (NDA) for Dasynoc®, following a Complete Response Letter (CRL) where additional information was requested. The FDA has now assigned a Prescription Drug User Fee Act (PDUFA) date to 31st of July, 2024. This is the FDA’s deadline for completing the approval process, marking a significant milestone for Das
Business WireXspray Pharma’s XS003 Achieves Superior Bioavailability Milestone, Matching TASIGNA® at Reduced Dosage
STOCKHOLM, November 21, 2023--Xspray Pharma AB (Stockholm/Nasdaq: XSPRAY) a biotechnology company developing improved PKIs for cancer treatment, through its proprietary HyNap™ technology, today announced that XS003, its amorphous, non-crystalline formulation of nilotinib, has demonstrated bioavailability within the 80-125% range to TASIGNA® following oral administration with significantly lower dose. This is the second of three announced amorphous PKIs under development by Xspray using the HyNap
Business WireDASYNOC™ Uptake into the Blood Remains Consistent When Taken with Omeprazole, Whereas SPRYCEL® Uptake is Significantly More Impaired than Previously Understood
STOCKHOLM, November 08, 2023--Xspray Pharma AB (Stockholm/Nasdaq: XSPRAY) a biotechnology company developing improved TKIs for cancer treatment, through its proprietary HyNap™ technology, today announced the results from drug interaction studies demonstrating that DASYNOC’s (DASYNOC CO-PPI Study) uptake into blood following oral dosing is not altered by the concomitant administration of omeprazole, a commonly prescribed PPI, while a significant reduction in the uptake of SPRYCEL (SPRYCEL CO-PPI
